940 related articles for article (PubMed ID: 15126145)
1. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
2. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B
Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
5. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods.
Iqbal NJ; Boey A; Park BJ; Brandt ME
Diagn Microbiol Infect Dis; 2008 Nov; 62(3):348-50. PubMed ID: 18707841
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
Arredondo-García JL; Amábile-Cuevas CF;
J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
Morace G; Polonelli L;
Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China.
Xie L; Zhai H; Zhao J; Sun S; Shi W; Dong X
Am J Ophthalmol; 2008 Aug; 146(2):260-265. PubMed ID: 18547535
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
12. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
14. Exogenous fungal endophthalmitis: microbiology and clinical outcomes.
Wykoff CC; Flynn HW; Miller D; Scott IU; Alfonso EC
Ophthalmology; 2008 Sep; 115(9):1501-7, 1507.e1-2. PubMed ID: 18486220
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
16. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
[TBL] [Abstract][Full Text] [Related]
17. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of a buffered chelating solution as an antimicrobial potentiator for antifungal drugs against fungal pathogens obtained from horses with mycotic keratitis.
Weinstein WL; Moore PA; Sanchez S; Dietrich UM; Wooley RE; Ritchie BW
Am J Vet Res; 2006 Apr; 67(4):562-8. PubMed ID: 16579746
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens.
Yenişehirli G; Bulut Y; Güven M; Günday E
J Laryngol Otol; 2009 Sep; 123(9):978-81. PubMed ID: 19454132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
